Showing 4871-4880 of 7372 results for "".
- Aquaphor Partners with NBCUniversal and Giselle Blondet for New Campaignhttps://practicaldermatology.com/news/aquaphor-partners-with-nbcuniversal-and-telemundo-personality-giselle-blondet-for-new-campaign/2462084/Aquaphor is partnering with NBCUniversal and Telemundo personality Giselle Blondet to showcase the multiple uses of Aquaphor Baby Healing Ointment across generations. "Aquaphor Baby has been part of our family for many years. What you see is a perfect reflection of my rel
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi
- Pinpointing BNP’s Role in ADhttps://practicaldermatology.com/news/pinpointing-bnps-role-in-ad/2462082/The brain natriuretic peptide (BNP) may play a role in activating atopic dermatitis, according to new research in mice. “BNP is expressed in sensory neurons, the neurons responsible for conveying sensation to the brain via the spinal cord,” says Santosh Mishra, associate pro
- Exploring OX40’s Role in AD: A Conversation With Dr. Stephan Weidingerhttps://practicaldermatology.com/news/exploring-ox40s-role-in-ad-a-conversation-with-dr-stephan-weidinger/2462078/The anti-Ox40-ligand antibody amlitelimab performed well in the phase 2b Stream-AD trial of adults with moderate-to-severe atopic dermatitis, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. Amlitelimab demonstrated c
- Almost Half of All Skin Disease Patients Report Sleep Issueshttps://practicaldermatology.com/news/almost-half-of-all-skin-disease-patients-report-sleep-issues/2462075/Almost half of all patients with skin disease report sleep disturbances, finds new research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. The ALL PROJECT analyzed data on more than 50,000 adults across 20 countries to assess the impact
- Lebrikizumab Update: IL-13 Blocker Performs Well in AD Inadequately Controlled With Cyclosporinehttps://practicaldermatology.com/news/lebrikizumab-update-il-13-blocker-performs-well-in-ad-inadequately-controlled-with-cyclosporine/2462070/Lebrikizumab showed clinical improvements in combination with topical corticosteroids (TCS) in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD) that was not adequately controlled with cyclosporine or for whom cyclosporine was not medically adv
- Tralokinumab Controls AD Over the Long Termhttps://practicaldermatology.com/news/adtralza-tralokinumab-controls-ad-over-the-long-term/2462069/Continuous use of Leo Pharma’s Adtralza (tralokinumab) provided long-term disease control in adult patients with moderate-to-severe atopic dermatitis (AD), according to a post hoc, interim, subgroup analysis of the ongoing ECZTEND study presented at the European Academy of Dermatology and V
- EADV News: Bimekizumab Achieves High Thresholds of Clinical Response in HShttps://practicaldermatology.com/news/eadv-news-bimekizumab-achieves-high-thresholds-of-clinical-response-in-hs/2462067/UCB’s Bimekizumab treatment results in clinically meaningful improvements in Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) and the more stringent HiSCR75, HiSCR90 and HiSCR100 compared with placebo at Week 16, with improvements increasing for patients remaining in the study t
- EADV News: Continued Treatment with Opzelura (Ruxolitinib) Cream Shows Efficacy in Nonsegmental Vitiligohttps://practicaldermatology.com/news/eadv-news-continued-treatment-with-opzelura-ruxolitinib-cream-shows-efficacy-in-nonsegmental-vitiligo/2462059/Nonsegmental vitiligo patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura (Ruxolitinib) Cream for up to two years, according to new results of a pooled analysis of long-term ext
- Industry Vet Brent Hauser Named President, International at Cuterahttps://practicaldermatology.com/news/industry-vet-brent-hauser-named-president-international-at-cutera/2462034/Brent Hauser is the new President, International, at Cutera, Inc. Mr. Hauser will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the inter